Amgen Launches Assistance Program for NSCLC Biomarker Testing
FDA Approves Nivolumab in Combination with Chemotherapy for Three Indications
FDA Approves Sacituzumab Govitecan-hziy for Urothelial Cancer
FDA Approves Sacituzumab Govitecan-hziy for Triple-Negative Breast Cancer
AONN+ Leadership Council Shares Need for Complete Cancer Care Team
FDA Grants Breakthrough Device Designation to miR Scientific Assay
CMS Releases New Billing Codes for April 2021
FDA Approves Isatuximab in Combination for R/R Multiple Myeloma
Eisai and Advocacy Leaders Launch Initiative to Highlight Edometrial Cancer
FDA Approves Daunorubicin + Cytarabine for Secondary Acute Myeloid Leukemia
FDA Approves Idecabtagene Vicleucel for R/R Multiple Myeloma
Bayer Announces No-Cost Genetic Testing Programs for NTRK Gene Fusions
FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma
FDA Approves TheraSphere Y-90 Glass Microspheres for Patients With HCC
FDA Approves Tivozanib for R/R Advanced RCC
The USPSTF Announces Update to Lung Cancer Screening Recommendations
The FDA Approves Axicabtagene Ciloleucel for R/R Follicular Lymphoma
FDA Expands Lorlatinib Approval to Include ALK-Positive NSCLC
FDA Issues EUA for Third COVID-19 Vaccine
FDA Approves Melphalan Flufenamide for R/R MM
FDA Approves the PD-L1 IHC 22C3 pharmDx Assay for NSCLC
FDA Approves Cemiplimab-rwlc Monotherapy for Advanced NSCLC
FDA Approves Trilaciclib for Chemotherapy-Induced Myelosuppression in ES-SCLC
U.S. Hospitals Request the Reversals of the 340B-Drug and Pay Cuts Rulings
FDA Issues EUA for Bamlanivimab and Etesevimab for COVID-19 Treatment
FDA Approves Cemiplimab-rwlc as First Immunotherapy for Advanced BCC
FDA Approves Lisocabtagene Maraleucel for R/R Large B-Cell Lymphoma
FDA Grants Accelerated Approval to Umbralisib for Two Indications
FDA Approves Tepotinib for Metastatic NSCLC
FDA Approves Nivolumab + Cabozantinib for Advanced RCC
